CD79A and COVID-19: Nevertheless, our results are in accordance with previous studies indicating a rapid decay in anti-SARS-CoV-2 antibodies in patients40,47 and with a recent report showing a loss in nAb activity that mirrored the reduction in antigen-specific IgA and IgM.46 Of note, relative stability of anti-RBD antibodies was observed in a cohort of 15 COVID-19 patients,48–50 which indicates that the kinetics of nAb activity in patients need to be further evaluated with alternative COVID-19 cohorts and more patients.